EZH2 silencing with RNAi enhances irradiation-induced inhibition of human lung cancer growth in vitro and in vivo

Xia,Hui; Yu,Chang-Hai; Zhang,Yiming; Yu,Jianqi; Li,Jie; Zhang,Wen; Zhang,Baoshi; Li,Yingjie; Guo,Nannan

doi:10.3892/ol.2012.696

EZH2 silencing with RNAi enhances irradiation-induced inhibition of human lung cancer growth in vitro and in vivo

Authors:
- Hui Xia
- Chang-Hai Yu
- Yiming Zhang
- Jianqi Yu
- Jie Li
- Wen Zhang
- Baoshi Zhang
- Yingjie Li
- Nannan Guo
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, First Affiliated Hospital of PLA General Hospital, Beijing 100048, P.R. China
Published online on: April 26, 2012 https://doi.org/10.3892/ol.2012.696
Pages: 135-140

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-small cell lung cancer (NSCLC) has a high mortality rate and poor prognosis. The aim of the present study was to silence EZH2 and explore the antitumor effect of small interfering RNA (siRNA)-EZH2 in combination with radiotherapy, which is a main treatment for NSCLC. The results showed that irradiation in the presence of siRNA-EZH2 arrested A549 cells in the G0 and G1 phases, delayed cell cycle progression and effectively inhibited cell proliferation, compared with cells that received radiotherapy alone. The combined therapy enhanced the percentage of apoptotic A549 cells in vitro and reduced the tumor size, in addition to increasing the survival rate in tumor xenograft experiments. This study demonstrates the antitumor activity of ionizing radiation therapy in combination with siRNA-EZH2 in NSCLC, both in vitro and in vivo, as well as providing a scientific rationale for targeting EZH2 to enhance the sensitivity of cancer to radiotherapy in NSCLC patients.

View Figures

View References

1	Fidias P and Novello S: Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J Clin Oncol. 28:5116–5123. 2010. View Article : Google Scholar : PubMed/NCBI
2	Fuld AD, Dragnev KH and Rigas JR: Pemetrexed in advanced non-small-cell lung cancer. Expert Opin Pharmacother. 11:1387–1402. 2010. View Article : Google Scholar : PubMed/NCBI
3	Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, Minna JD, Michnoff C, Hao W, Roth MG, et al: Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature. 446:815–819. 2007. View Article : Google Scholar : PubMed/NCBI
4	Francis H and Solomon B: The current status of targeted therapy for non-small cell lung cancer. Intern Med J. 40:611–618. 2010. View Article : Google Scholar : PubMed/NCBI
5	Suvà ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, et al: EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 69:9211–9218. 2009.PubMed/NCBI
6	Lennes IT and Lynch TJ: Quality indicators in cancer care: development and implementation for improved health outcomes in non-small-cell lung cancer. Clin Lung Cancer. 10:341–346. 2009. View Article : Google Scholar : PubMed/NCBI
7	Yamaguchi J, Sasaki M, Sato Y, Itatsu K, Harada K, Zen Y, Ikeda H, Nimura Y, Nagino M and Nakanuma Y: Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma. Cancer Sci. 101:355–362. 2010. View Article : Google Scholar : PubMed/NCBI
8	Fujii S, Ito K, Ito Y and Ochiai A: Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem. 283:17324–17332. 2008. View Article : Google Scholar : PubMed/NCBI
9	Tsang DP and Cheng AS: Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J Gastroenterol Hepatol. 26:19–27. 2011. View Article : Google Scholar : PubMed/NCBI
10	Gonzalez ME, Li X, Toy K, DuPrie M, Ventura AC, Banerjee M, Ljungman M, Merajver SD and Kleer CG: Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene. 28:843–853. 2009. View Article : Google Scholar : PubMed/NCBI
11	Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, et al: Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 114:2733–2743. 2009. View Article : Google Scholar
12	Panousis D, Patsouris E, Lagoudianakis E, Pappas A, Kyriakidou V, Voulgaris Z, Xepapadakis G, Manouras A, Athanassiadou AM and Athanassiadou P: The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors. Eur J Gynaecol Oncol. 32:156–159. 2011.PubMed/NCBI
13	Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N and Rotter V: Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene. 23:5759–5769. 2004. View Article : Google Scholar : PubMed/NCBI